Multi-drug resistant strains as etiological agents of urinary tract infections in patients after solid organ transplantation.


Journal

Przeglad epidemiologiczny
ISSN: 0033-2100
Titre abrégé: Przegl Epidemiol
Pays: Poland
ID NLM: 0413725

Informations de publication

Date de publication:
2023
Historique:
medline: 1 11 2023
pubmed: 11 10 2023
entrez: 11 10 2023
Statut: ppublish

Résumé

Urinary tract infections (UTIs) caused by multi-drug resistant strains are a serious and growing problem in organ transplant (TX) recipients. The aim of the study was to assess the prevalence and risk factors of UTIs caused by multi-drug resistant strains in hospitalized patients after kidney or liver transplantation in a large transplant center. 392 cases of UTIs in patients after kidney or liver TX hospitalized in 2014, 2015 and 2016 were analyzed. Among the assessed cases of UTIs, 66.07% occurred in women, 33.93% - in men, 80.1% - in kidney TX recipients and 19.9% - in liver TX recipients. The median age of the patients was 57.51 years and the median time since TX was 41.44 months. Most episodes of UTIs were observed during the first year after TX - 121 (30.78%) of cases. A total of 506 pathogens were cultured: 345 Gram-negative bacteria (68.182%), 146 Gram-positive bacteria (28.854%) and 15 fungi (2.964%). More than one pathogen was found in 25.51% of urine cultures. Among bacteria (n=491), a resistance mechanism was detected in 166 (33.81%) pathogens (133 Gram-negative and 33 Gram-positive). The most common etiological agents were: E. coli ESBL- (23.72%), K. pneumoniae ESBL+ (17.19%), E. faecalis (11.27%) and E. faecium (7.71%). Diabetes was present in 129 (35.46%) of patients, and the number of UTI cases was similar in the group with and without diabetes. Compared to the general population, in hospitalized patients after kidney or liver transplantation UTIs occur more often in men and are more often caused by Gram-positive bacteria. In 33.81% of cases UTIs are caused by multi-drug resistant strains, predominantly Gram-negative bacteria.

Identifiants

pubmed: 37818661
doi: 10.32394/pe.77.12
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

127-135

Informations de copyright

National Institute of Public Health NIH – National Research Institute.

Déclaration de conflit d'intérêts

Authors declare no conflict of interest.

Auteurs

Piotr Wilkowski (P)

Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Poland.

Ewa Hryniewiecka (E)

Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Poland.

Kornelia Jasińska (K)

Chair and Department of Medical Microbiology, Medical University of Warsaw, Poland.

Michał Ciszek (M)

Department of Immunology, Transplantology and Internal Diseases, Medical University of Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH